{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:57:25Z","timestamp":1793055445377,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lysosomal storage diseases (LSDs) can be treated with intravenous enzyme replacement therapy (ERT). ERT is being administered either in specialized clinics or in the home care setting. Studies indicate that home-based ERT can be considered safe and positively effects patient reported outcomes. Due to the higher level of individual care required by nurses when administering ERT at home, questions arise whether this will result in additional costs for health care systems. Since cost data to the German health care system are currently unavailable, this study aims to assess home care ERT costs of LSD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The longitudinal study assessed the direct costs of home-based ERT for patients with LSD diseases Fabry, Pompe, Gaucher, and MPS I from 2019 to 2021 on a patient-by-patient basis by evaluating the healthcare documentation. Costs assessed included ERT drug and further administration equipment, time needed to prepare, administer, and post-process the infusion, and travel expenses of nursing staff.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 62 patients was analyzed: of these, 29 (46.8%) with Fabry disease, 19 (30.6%) with Pompe disease, 10 (16.1%) with Gaucher disease, and 4 (6.5%) with MPS I. Patients ranged in age from 3 to 79 (mean 40 years); 42% of patients reported comorbidities (19.4% with hypertension, and 10% with heart disease). Mean total ERT-related costs were \u20ac369,047 per year across all patients. Approximately 98.5% of these costs were attributable to the infusion therapy and administration itself (\u20ac363,880), and approximately 1.5% were attributable to personnel and travel costs. Patients with Pompe disease incurred the highest average annual costs (\u20ac483,907) and patients with Fabry disease the lowest (\u20ac264,896). Cost differences among underlying LSDs were due primarily to ERT drug costs; the drug infused for Fabry disease costs about half as much as that for Gaucher or for Pompe disease. Despite MPS I patients requiring about twice as many infusions, significantly lower drug costs for this disease resulted in the second lowest total mean costs of all LSD subtypes analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>As total costs are almost entirely driven by infusion-related material, especially the ERT drug, moving ERT into the home environment is not expected to increase costs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03492-4","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T09:31:35Z","timestamp":1734341495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Health care costs of home care enzyme replacement therapy for patients with lysosomal storage diseases in Germany"],"prefix":"10.1186","volume":"19","author":[{"given":"Ria","family":"Heinrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-4191","authenticated-orcid":false,"given":"Tonio","family":"Schoenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"3492_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1055\/s-0043-103088","volume":"229","author":"AM Das","year":"2017","unstructured":"Das AM, Lagler F, Beck M, Scarpa M, Lampe C. Lysosomale speichererkrankungen: herausforderungen bei der sektor\u00fcbergreifenden, multiprofessionellen patientenversorgung mit enzymersatztherapie. Klin Padiatr. 2017;229:168\u201374. https:\/\/doi.org\/10.1055\/s-0043-103088.","journal-title":"Klin Padiatr"},{"key":"3492_CR2","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1055\/s-0033-1349624","volume":"138","author":"M Beck","year":"2013","unstructured":"Beck M, Gaedeke J, Martus P, Karabul N, Rolfs A. Infusionsbehandlung in h\u00e4uslicher umgebung--ein praktikabler Ansatz f\u00fcr chronisch kranke? Dtsch Med Wochenschr. 2013;138:2345\u201350. https:\/\/doi.org\/10.1055\/s-0033-1349624.","journal-title":"Dtsch Med Wochenschr"},{"key":"3492_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tins.2011.05.006","volume":"34","author":"ML Schultz","year":"2011","unstructured":"Schultz ML, Tecedor L, Chang M, Davidson BL. Clarifying lysosomal storage diseases. Trends Neurosci. 2011;34:401\u201310. https:\/\/doi.org\/10.1016\/j.tins.2011.05.006.","journal-title":"Trends Neurosci"},{"key":"3492_CR4","unstructured":"Das F\u00fcnfte Buch Sozialgesetzbuch\u2013Gesetzliche Krankenversicherung: SGB V; 28.06.2022."},{"key":"3492_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/acn3.51745","volume":"10","author":"B Barrera","year":"2023","unstructured":"Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-Gonz\u00e1lez J, et al. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023;10:579\u201388. https:\/\/doi.org\/10.1002\/acn3.51745.","journal-title":"Ann Clin Transl Neurol"},{"key":"3492_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.hjdsi.2016.04.004","volume":"5","author":"JM Polinski","year":"2017","unstructured":"Polinski JM, Kowal MK, Gagnon M, Brennan TA, Shrank WH. Home infusion: Safe, clinically effective, patient preferred, and cost saving. Healthcare. 2017;5:68\u201380. https:\/\/doi.org\/10.1016\/j.hjdsi.2016.04.004.","journal-title":"Healthcare"},{"key":"3492_CR7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.neurol.2023.01.727","volume":"179","author":"J-C Lafontaine","year":"2023","unstructured":"Lafontaine J-C, Boucher J, Giovannelli J, Petit J, Outteryck O, Balagny S, Z\u00e9phir H. Evaluation of risk management in a natalizumab home infusion procedure. Rev Neurol. 2023;179:894\u2013901. https:\/\/doi.org\/10.1016\/j.neurol.2023.01.727.","journal-title":"Rev Neurol"},{"key":"3492_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymgmr.2017.06.005","volume":"12","author":"D Concolino","year":"2017","unstructured":"Concolino D, Amico L, Cappellini MD, Cassinerio E, Conti M, Donati MA, et al. Home infusion program with enzyme replacement therapy for Fabry disease: the experience of a large Italian collaborative group. Mol Genet Metab Rep. 2017;12:85\u201391. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.06.005.","journal-title":"Mol Genet Metab Rep"},{"key":"3492_CR9","unstructured":"ABDA. ABDA Datenbank; 20.09.2021."},{"key":"3492_CR10","unstructured":"Bundesministerium f\u00fcr Justiz. Einkommensteuergesetz (EStG)\u2013\u00a79 Werbungskosten; 2023."},{"key":"3492_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. Psychol Bull. 1992;112:155\u20139. https:\/\/doi.org\/10.1037\/0033-2909.112.1.155.","journal-title":"Psychol Bull"},{"key":"3492_CR12","first-page":"120","volume":"106","author":"M Buraczewska","year":"2013","unstructured":"Buraczewska M, O\u2019Leary D, Walsh O, Monavari A, Crushell E. Parental experience of enzyme replacement therapy for Hunter syndrome. Ir Med J. 2013;106:120\u20132.","journal-title":"Ir Med J"},{"key":"3492_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s10545-007-0686-8","volume":"30","author":"J Cox-Brinkman","year":"2007","unstructured":"Cox-Brinkman J, Timmermans RGM, Wijburg FA, Donker WE, van de Ploeg AT, Aerts JMFG, Hollak CEM. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. J Inherit Metab Dis. 2007;30:984. https:\/\/doi.org\/10.1007\/s10545-007-0686-8.","journal-title":"J Inherit Metab Dis"},{"key":"3492_CR14","doi-asserted-by":"publisher","first-page":"100971","DOI":"10.1016\/j.ymgmr.2023.100971","volume":"35","author":"R Heinrich","year":"2023","unstructured":"Heinrich R, Claus F, Schoenfelder T. The patients` perspective on home-based infusion: a longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy. Mol Genet Metab Rep. 2023;35:100971. https:\/\/doi.org\/10.1016\/j.ymgmr.2023.100971.","journal-title":"Mol Genet Metab Rep"},{"key":"3492_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1365-2362.2010.02458.x","volume":"41","author":"JF Guest","year":"2011","unstructured":"Guest JF, Concolino D, Di Vito R, Feliciani C, Parini R, Zampetti A. Modelling the resource implications of managing adults with Fabry disease in Italy. Eur J Clin Invest. 2011;41:710\u20138. https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02458.x.","journal-title":"Eur J Clin Invest"},{"key":"3492_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16390","volume":"16","author":"K Wyatt","year":"2012","unstructured":"Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16:1\u2013543. https:\/\/doi.org\/10.3310\/hta16390.","journal-title":"Health Technol Assess"},{"key":"3492_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ajh.24957","volume":"93","author":"A Zimran","year":"2018","unstructured":"Zimran A, Belmatoug N, Bembi B, Deegan P, Elstein D, Fernandez-Sasso D, et al. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the gaucher outcome survey (GOS). Am J Hematol. 2018;93:205\u201312. https:\/\/doi.org\/10.1002\/ajh.24957.","journal-title":"Am J Hematol"},{"key":"3492_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis. 2007;30:184\u201392. https:\/\/doi.org\/10.1007\/s10545-007-0521-2.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03492-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03492-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03492-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T10:02:21Z","timestamp":1734343341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03492-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3492"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03492-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. RH, FC and TS are all employees of WIG2 GmbH, which is an independent institute and paid consultant to Sanofi Aventis Deutschland GmbH for designing the study, carrying out the analyses, interpreting the results and writing the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}